Merck Shares Tumble 5.32% Amidst Tariff Talk Turmoil

On April 10, shares of Merck (MRK) experienced a notable drop of 5.32%, hitting their lowest price since March 2022 during intraday trading. The decline reflects broader market movements amidst discussions about potential import tariffs on pharmaceuticals, as announced by former President Donald Trump. Merck, alongside competitors Eli Lilly and Pfizer, faced significant stock depreciation in response.

Earlier, on April 5, Merck's stock faced another downturn, dipping 5.02% to close at $82.05 per share. The company's total market valuation remains robust, standing at approximately $207.61 billion despite these fluctuations. The financial data for Merck, up to December 31, 2024, reveals a revenue of $641.68 billion and a remarkable net profit increase to $171.17 billion, demonstrating significant growth year-over-year.

Merck's upcoming fiscal report is set to unveil its 2025 first-quarter earnings before market opens on April 24. As a leading entity in global biopharmaceutical innovation, Merck continues to prioritize the development and delivery of medical solutions for some of the world's most challenging diseases, including various forms of cancer, cardiovascular conditions, and emerging infectious diseases such as Ebola and HIV.